- Sona Nanotech (CSE:SONA) completed treatment and follow-up for the first cohort in its first-in-human study of Targeted Hyperthermia Therapy (THT) for late-stage melanoma, showing promising early results
- Approval for the second patient cohort has been granted, with chief medical officer Dr. Carman Giacomantonio arriving in Santiago to oversee the next phase of treatments
- THT uses biocompatible gold nanorods to deliver therapeutic heat to tumors, aiming to stimulate immune response, shrink tumors, and enhance drug delivery with minimal invasiveness
- Sona Nanotech stock (CSE:SONA) opened trading at $0.59
Oncology-focused life sciences company, Sona Nanotech (CSE:SONA), has announced a significant milestone in its first-in-human clinical trial of Targeted Hyperthermia Therapy (THT), a novel cancer treatment utilizing its proprietary biocompatible gold nanorod technology.
This content has been prepared in collaboration with Sona Nanotech Inc., a third-party issuer, and is intended for informational purposes only.
The company has successfully completed treatment and follow-up assessments for the first cohort of late-stage melanoma patients in its early feasibility study. Encouraged by the absence of significant adverse health events and early signs of clinical response, Sona has received approval to proceed with a second cohort. Chief medical officer Dr. Carman Giacomantonio arrived in Santiago this past weekend to oversee the next phase of treatments.
THT is a photothermal cancer therapy that delivers therapeutic heat (42–48°C) directly to tumors via infrared light absorbed and re-emitted by Sona’s gold nanorods. This heat stimulates the immune system, shrinks tumors, inactivates cancer stem cells, and enhances drug delivery by increasing tumor perfusion. The therapy is designed to be safe, minimally invasive, and cost-effective, making it a potential adjunct to existing cancer treatments.
In a news release, David Regan, CEO of Sona Nanotech, emphasized the broader implications of the study: “We are encouraged by the progress of our first-in-human clinical study and pleased to be progressing toward having validating clinical data that will further complement our existing preclinical data. We also excitedly anticipate additional scientific insights into our novel technology from studies planned for submission to leading scientific journals in the fall that, combined with our clinical study, will provide for a more comprehensive data package. Furthermore, with our previously announced ethics approval secured for a larger clinical trial in Canada, we are currently working to incorporate the significant learnings to date from our Early Feasibility Study into our application to Health Canada.”
“As we proceed with the second cohort of patients, we have reason for optimism based on early clinical responses and tumor biopsy results for patients treated so far,” CMO Giacomantonio, added.
This comes just over a month since Sona dosed the first patient in its early feasibility study.
Sona’s gold nanorods are uniquely CTAB-free, eliminating toxicity risks associated with other nanorod technologies, and positioning the company at the forefront of safe nanomedicine innovation.
The company aims to complete the targeted number of patients by the end of September, followed by extensive scientific analysis to assess immune engagement in treated tumors. If successful, this could mark a major step in cancer therapy, particularly for patients unresponsive to conventional immunotherapies.
Sona Nanotech operates out of Halifax, Nova Scotia and is a company developing Targeted Hyperthermia, a photothermal cancer therapy, which uses therapeutic heat to treat solid cancer tumors.
Sona Nanotech stock (CSE:SONA) opened trading 1.72 per cent higher at $0.59.
Join the discussion: Find out what the Bullboards are saying about SonaNanotech and check out Stockhouse’s stock forums and message boards.
Stockhouse does not provide investment advice or recommendations. All investment decisions should be made based on your own research and consultation with a registered investment professional. The issuer is solely responsible for the accuracy of the information contained herein. For full disclaimer information, please click here.